Sökning: "Tolerability"

Visar resultat 1 - 5 av 46 avhandlingar innehållade ordet Tolerability.

  1. 1. Preclinical Studies for Cryoprevention of Oral Mucositis

    Författare :Java Walladbegi; Göteborgs universitet; []
    Nyckelord :MEDICIN OCH HÄLSOVETENSKAP; MEDICAL AND HEALTH SCIENCES; MEDICIN OCH HÄLSOVETENSKAP; MEDICAL AND HEALTH SCIENCES; MEDICIN OCH HÄLSOVETENSKAP; MEDICAL AND HEALTH SCIENCES; Animal model; Chemotherapy; Cryotherapy; Hematopoietic stem cell transplantation; Ice chips; Intraoral cooling device; Microcirculation; Randomized controlled trial; Tissue-engineered oral mucosa; Tissue oxygen saturation; Tolerability;

    Sammanfattning : Oral mucositis (OM) is a debilitating adverse effect, with a prevalence of up to 80% in patients with cancer who are conditioned with high-dose chemotherapy prior to hematopoietic stem cell transplantation. In its mildest form, OM is characterized by erythema. However, as it worsens, it can give rise to painful ulcerations in the oral mucosa. LÄS MER

  3. 2. Anti-TNF treatment of chronic arthritis in clinical practice. New assessment method and predictors of efficacy and tolerability

    Författare :Lars Erik Kristensen; Reumatologi och molekylär skelettbiologi; []
    Nyckelord :MEDICIN OCH HÄLSOVETENSKAP; MEDICAL AND HEALTH SCIENCES; response; drug survival; psoriatic arthritis; Arthritis; rheumatoid arthritis; adverse events; TNF antagonists;

    Sammanfattning : Abstract Treatment of chronic inflammatory arthritis has undergone major changes over the past years following introduction of targeted biological therapies. Tumour necrosis factor (TNF) blocking therapy has been the most important biological treatment of chronic arthritis to date. LÄS MER

  4. 3. Anti-CD20 therapy in multiple sclerosis : clinical and paraclinical outcomes

    Författare :Alexander Juto; Karolinska Institutet; Karolinska Institutet; []
    Nyckelord :;

    Sammanfattning : Multiple sclerosis is a chronic inflammatory disease of the central nervous system and the most common non-traumatic cause of neurological disability in young adults. Rituximab is a B-cell depleting drug targeting the CD20 epitope on B-cells, which drive inflammation in relapsing-remitting multiple sclerosis by acting as antigen-presenting cells to activate T-cell responses against central nervous system autoantigens. LÄS MER

  5. 4. Mantle cell lymphoma strategies in primary treatment

    Författare :Alexandra Albertsson Lindblad; Tumörmikromiljö; []
    Nyckelord :MEDICIN OCH HÄLSOVETENSKAP; MEDICAL AND HEALTH SCIENCES; mantle cell lymphoma; registry data; Clinical Trial; Phase I; Clinical Trial; Phase II; rituximab; bendamustine; lenalidomid; ibrutinib; ADCC; in vitro model; TP53 mutations; watchful waiting; mantle cell lymphoma; real-world data; lenalidomide; rituximab; bendamustin; ibrutinib; ADCC; TP53 mutation; CDKN2A; NGS; MIPI; Watchful waiting;

    Sammanfattning : Mantle cell lymphoma (MCL) is associated with poor prognosis due to an aggressive clinical course. Being a rare disease, there are few randomized trials in MCL and there is no defined golden standard in primary treatment. LÄS MER

  7. 5. Nerve growth factor in Alzheimer’s disease : biological effects and therapeutic potential

    Författare :Helga Eyjolfsdottir; Karolinska Institutet; Karolinska Institutet; []
    Nyckelord :;

    Sammanfattning : Alzheimer’s disease (AD) is a progressive neurodegenerative disorder against which there is yet no disease modifying or curative treatment. Degeneration of cholinergic basal forebrain (CBF) neurons plays a role in the pathogenesis of AD and these neurons are highly dependent on nerve growth factor (NGF) for growth and survival. LÄS MER